Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma

被引：0
|
作者：
Okay, M. [1 ]
Buyukasik, Y. [1 ]
Demiroglu, H. [1 ]
Malkan, U. [2 ]
Ciftciler, R. [1 ]
Aladag, E. [1 ]
Aksu, S. [1 ]
Haznedaroglu, I. [1 ]
Sayinalp, N. [1 ]
Ozcebe, O. [1 ]
Goker, H. [1 ]
机构：
[1] Hacettepe Univ, Ankara, Turkey
[2] Univ Hlth Sci, Diskapi Yildirim Beyazit Training & Res Hosp, Ankara, Turkey
来源：
LEUKEMIA RESEARCH | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OP-23
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
    Okay, Mufide
    Buyukasik, Yahya
    Demiroglu, Haluk
    Malkan, Umit Yavuz
    Ciftciler, Rafiye
    Aladag, Elifcan
    Aksu, Salih
    Haznedaroglu, Ibrahim Celalettin
    Sayinalp, Nilgun
    Ozcebe, Osman Ilhami
    Goker, Hakan
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2019, 49 (04) : 985 - 992
  • [2] A Retrospective Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphoma Patients
    Halacoglu, Aysun
    Serefhanoglu, Songul
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (01) : 92 - 98
  • [3] A Retrospective Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Lymphoma Patients
    Aysun Halacoglu
    Songul Serefhanoglu
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 92 - 98
  • [4] Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
    Shabbir-Moosajee, Munira
    Jehangir, Samad
    Sawani, Sobiya
    Muhammed, Tariq
    Ali, Natasha
    Sheikh, Usman
    Adil, Salman
    BLOOD RESEARCH, 2019, 54 (02) : 108 - 113
  • [5] High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma
    Fernandez-Gutierrez, Jose A.
    Reyes-Cisneros, Oscar A.
    Litzow, Mark R.
    Bojalil-Alvarez, Lorena
    Garcia-Villasenor, Elizabeth
    Tomas Gomez-Gomez, Eliezer
    Murrieta-Alvarez, Ivan
    Gomez-Almaguer, David
    Gutierrez-Aguirre, Cesar H.
    Karduss-Urueta, Amado J.
    Ruiz-Delgado, Guillermo J.
    Jose Ruiz-Arguelles, Guillermo
    HEMATOLOGY, 2022, 27 (01) : 449 - 455
  • [6] High-dose etoposide, cytarabine and melphalan as conditioning regimen for autologous stem cell transplantation in patients with refractory or relapsed Hodgkin's lymphoma
    Bekadja, M. A.
    Osmani, S.
    Brahimi, M.
    Talhi, S.
    Bekadja, S.
    Belkhodja, S.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S446 - S446
  • [7] Mitoxantrone and melphalan as conditioning regimen for autologous stem cell transplant for multiple myeloma.
    Beaven, Anne W.
    Comeau, Terrance
    Sharf, Andrew
    Moore, Dominic T.
    Serody, Jonathan
    Shea, Thomas C.
    Gabriel, Don A.
    BLOOD, 2006, 108 (11) : 834A - 834A
  • [8] Mitoxantrone and melphalan as a conditioning regimen for autologous peripheral blood stem cell transplantation in adults with acute myelogenous leukemia
    Sprague, KA
    Padgaonkar, VA
    Klein, AK
    Chan, GW
    Miller, KB
    Klingemann, H
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 93 - 94
  • [9] Improved Outcome with Busulfan, Melphalan, and Thiotepa Conditioning (BuMelTt) in Autologous Hematopoietic Stem Cell Transplantation for Relapsed/Refractory; Hodgkin Lymphoma
    Bains, Tarunpreet
    Phd, Andy I. ChenMd
    Lemieux, Andrew
    Hayes-Lattin, Brandon
    Leis, Jose F.
    Maziarz, Richard T.
    BLOOD, 2011, 118 (21) : 1344 - 1344
  • [10] Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma
    Grisariu, Sigal
    Shapira, Michael Y.
    Or, Reuven
    Avni, Batia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (04): : 272 - 279
12345